<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JAA</journal-id>
<journal-id journal-id-type="hwp">spjaa</journal-id>
<journal-title>Journal of Asthma &amp; Allergy Educators</journal-title>
<issn pub-type="ppub">2150-1297</issn>
<issn pub-type="epub">2150-1300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2150129712472334</article-id>
<article-id pub-id-type="publisher-id">10.1177_2150129712472334</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Departments</subject>
<subj-group subj-group-type="heading">
<subject>Medication/Product Showcase</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Antihistamines</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Honey</surname><given-names>Brooke L.</given-names></name>
<degrees>PharmD, BCPS, AE-C</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>O’Neal</surname><given-names>Katherine S.</given-names></name>
<degrees>PharmD, MBA, BCACP, CDE, BC-ADM, AE-C</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Crosby</surname><given-names>Kim</given-names></name>
<degrees>PharmD, BCPS, CGP, CDE, BC-ADM</degrees>
</contrib>
</contrib-group>
<aff id="aff1-2150129712472334">Department of Pharmacy, Clinical and Administrative Sciences-Tulsa, University of Oklahoma College of Pharmacy, Tulsa, Oklahoma (BLH, KSO, KC)</aff>
<aff id="aff2-2150129712472334">Departments of Pediatrics (BLH) and Family Medicine (KC), University of Oklahoma School of Community Medicine, Tulsa, Oklahoma</aff>
<author-notes>
<corresp id="corresp1-2150129712472334">Brooke L. Honey, PharmD, BCPS, AE-C, University of Oklahoma College of Pharmacy, 4502 East 41st Street, Tulsa, OK 74135; e-mail: <email>brooke-honey@ouhsc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>4</volume>
<issue>4</issue>
<fpage>191</fpage>
<lpage>193</lpage>
<permissions>
<copyright-statement>© 2013 The Author(s)</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Histamine receptors are located throughout the body. The actions of histamine specifically at the H<sub>1</sub> receptors result in the signs and symptoms associated with allergic rhinitis and hypersensitivity reactions. Antihistamines block the activity of these H<sub>1</sub> receptors. There are 3 generations of antihistamines, with the first generation being the oldest. Available first-generation antihistamines used in the treatment of allergic rhinitis include chlorpheniramine, carbinoxamine, clemastine, cyproheptadine, dexchlorpheniramine, diphenhydramine, hydroxyzine, pheniramine, and triprolidine. Other first-generation antihistamines (promethazine, meclizine, dimenhydrinate, cyclizine, pyrilamine doxepin, and doxylamine) are indicated for use in the treatment of other conditions such as sleep disorders or motion sickness.<sup><xref ref-type="bibr" rid="bibr1-2150129712472334">1</xref>,<xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup></p>
<p>First-generation antihistamines are able to penetrate the blood–brain barrier well and may cause sedation, drowsiness, or cognitive impairment as a consequence of their activity in the central nervous system. When these agents are taken at night, significant “hangover effects” may be noticeable the following morning. Anticholinergic effects are another common adverse effect of the first-generation agents. Patients may notice dry mouth or eyes, urinary retention, hypotension, dilation of the pupils, or dizziness. Paradoxical excitation is a less commonly seen adverse effect that may be associated with the use of higher doses of first-generation antihistamines in children. Common symptoms associated with paradoxical excitation include insomnia, hyperactivity, and irritability.<sup><xref ref-type="bibr" rid="bibr3-2150129712472334">3</xref><xref ref-type="bibr" rid="bibr4-2150129712472334"/><xref ref-type="bibr" rid="bibr5-2150129712472334"/>-<xref ref-type="bibr" rid="bibr6-2150129712472334">6</xref></sup></p>
<p>The introduction of the “nonsedating” second-generation antihistamines provides an avenue for patients with medications that have less adverse effects and improved tolerability and safety profiles with equal efficacy compared to the first-generation antihistamines; hence, second-generation antihistamines tend to be recommended over first-generation antihistamines.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> The second-generation medications are more selective at the peripheral H<sub>1</sub> receptors, are larger molecules, and are not able to cross the blood–brain barrier as easily as the first-generation antihistamines.<sup><xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> Several of the second-generation antihistamines also block the release of mast cells and basophil inflammatory mediators.<sup><xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> Other advantages include having antimuscarinic, antiserotonin, and anti-α-adrenergic effects.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> Therefore, there are less sedating, impaired cognitive function, and anticholinergic effects associated with them.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> Of the 2 medications in this classification, cetirizine has a dose-dependent and highest incidence of sedation at 14%, whereas loratadine has an 8% incidence.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup> In addition, both these antihistamines have a longer duration of action, allowing for the convenience of once a day dosing (<xref ref-type="table" rid="table1-2150129712472334">Table 1</xref>).<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup> Both require hepatic and renal dosing adjustments.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup> Also noteworthy to mention, both cetirizine and loratadine have CYP3A4 drug interactions with commonly prescribed antibiotics (eg, clarithromycin, ciprofloxacin), cholesterol medications (eg, atorvastatin, lovastatin, simvastatin), and blood pressure medications (eg, diltiazem, verapamil).<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup></p>
<table-wrap id="table1-2150129712472334" position="float">
<label>Table 1.</label>
<caption>
<p>Antihistamine Agents<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref>,<xref ref-type="bibr" rid="bibr17-2150129712472334">17</xref>,<xref ref-type="table-fn" rid="table-fn2-2150129712472334">a</xref>,<xref ref-type="bibr" rid="bibr18-2150129712472334">18</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-2150129712472334" xlink:href="10.1177_2150129712472334-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Usual Dose<hr/></th>
<th/>
<th/>
<th/>
<th/>
</tr>
<tr>
<th align="center">Generation</th>
<th align="center">Medication</th>
<th align="center">Adults</th>
<th align="center">Children</th>
<th align="center">Rx/OTC</th>
<th align="center">Fetal Risk Factor</th>
<th align="center">Breast Feeding Recommendation</th>
<th align="center">Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>First generation</td>
<td>Carbinoxamine</td>
<td>4-8 mg 3-4 times daily</td>
<td>2-5 years: 1-2 mg 3-4 times daily; 6-11 years: 2-4 mg 3-4 times daily; ≥12 years: refer to adult dosing</td>
<td>Rx</td>
<td>C</td>
<td>No human data—probably compatible</td>
<td><italic>Adverse effects</italic>: Drowsiness/sedation, anticholinergic effects (dry mouth, urinary retention, blurred vision, confusion, impaired concentration, increased heart rate, constipation), paradoxical excitement (restlessness, nervousness, tremors, insomnia) in children</td>
</tr>
<tr>
<td/>
<td>Chlorpheniramine</td>
<td>IR: 4 mg q 4-6 hours; ER: 12 mg q 12 hours</td>
<td>2-5 years: 1 mg q 4-6 hours; 6-11 years: 2 mg q 4-6 hours; ≥12 years: refer to adult dosing</td>
<td>OTC</td>
<td>B</td>
<td>No human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Clemastine</td>
<td>1-2 tsp (1.34-2.68 mg) 1-3 times daily</td>
<td>6-11 years: 1 tsp (1.34 mg) twice daily; ≥12 years: refer to adult dosing</td>
<td>OTC</td>
<td>B</td>
<td>Limited human data—potential toxicity</td>
<td/></tr>
<tr>
<td/>
<td>Cyproheptadine</td>
<td>4-20 mg per day divided every 8 hours (do not exceed 0.5 mg/kg/d)</td>
<td>2-6 years: 2 mg q 8-12 hours (do not exceed 12 mg/d); 7-14 years: 4 mg q 8-12 hours (do not exceed 16 mg/d); ≥14 years: refer to adult dosing</td>
<td>Rx</td>
<td>B</td>
<td>No human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Dexchlorpheniramine</td>
<td>2 mg q 4-6 hours or 4-6 mg timed release at bedtime or q 8-10 hours</td>
<td>2-5 years: 0.5 mg q 4-6 hours; 6-11 years: 1 mg q 4-6 hours or 4 mg timed release at bedtime; ≥12: refer to adult dosing</td>
<td>Rx</td>
<td>B</td>
<td>No human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Diphenhydramine</td>
<td>25-50 mg q 4-6 hours</td>
<td>2-5 years: 6.25 mg q 4-6 hours; 6-11 years: 12.5-25 mg q 4-6 hours; ≥12 years: refer to adult dosing</td>
<td>OTC</td>
<td>B</td>
<td>Limited human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Hydroxyzine</td>
<td>25 mg q 6-8 hours</td>
<td>&lt;6 years: 50 mg/d in divided doses; ≥6 years: 50-100 mg/d in divided doses; alternative child dose: 2 mg/kg/d divided every 6-8 hours</td>
<td>Rx</td>
<td>C</td>
<td>No human data—probably compatible</td>
<td/></tr>
<tr>
<td>Second generation</td>
<td>Cetirizine (Zyrtec)</td>
<td>5-10 mg daily</td>
<td>6-12 months: 2.5 mg daily; 1-5 years: 2.5-5 mg daily; ≥6 years: 5-10 mg daily</td>
<td>OTC</td>
<td>B</td>
<td>No human data—probably compatible</td>
<td><italic>Adverse effects</italic>: drowsiness/sedation (cetirizine only), fatigue, dry mouth, headache, colds, back pain, pharyngitis</td>
</tr>
<tr>
<td/>
<td>Loratadine (Claritin, Alavert)</td>
<td>10 mg daily</td>
<td>2-5 years: 5 mg daily; ≥6 years: 10 mg daily</td>
<td>OTC</td>
<td>B</td>
<td>Limited human data—probably compatible</td>
<td/></tr>
<tr>
<td>Third generation<sup><xref ref-type="table-fn" rid="table-fn2-2150129712472334">b</xref></sup></td>
<td>Desloratadine (Clarinex)</td>
<td>5 mg daily</td>
<td>6-11 months: 1 mg daily; 1-5 years: 1.25 mg daily; 6-11 years: 2.5 mg daily; ≥12 years: refer to adult dosing</td>
<td>Rx</td>
<td>C</td>
<td>Limited human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Fexofenadine (Allegra)</td>
<td>60 mg twice daily or 180 mg daily</td>
<td>2-11 years: 30 mg twice daily; ≥12 years: refer to adult dosing</td>
<td>OTC</td>
<td>C</td>
<td>Limited human data—probably compatible</td>
<td/></tr>
<tr>
<td/>
<td>Levocetirizine (Xyzal)</td>
<td>5 mg daily</td>
<td>6 months-5 years: 1.25 mg daily; 6-11 years: 2.5 mg daily; ≥12 years: refer to adult dosing</td>
<td>Rx</td>
<td>B</td>
<td>No human data—probably compatible</td>
<td/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2150129712472334">
<label>a</label>
<p>Table only includes antihistamines commercially available in single ingredient products. Other antihistamine products and formulations are found in combination medications.</p>
</fn>
<fn id="table-fn2-2150129712472334">
<label>b</label>
<p>A number of studies consider these agents no different than the second-generation products.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The next group of antihistamines are commonly referred to as the third-generation antihistamines (<xref ref-type="table" rid="table1-2150129712472334">Table 1</xref>) and provide yet additional options for patients.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref>,<xref ref-type="bibr" rid="bibr8-2150129712472334">8</xref></sup> The 3 available medications are either metabolites or an enantiomer (respectively) of second-generation products—desloratadine (loratadine), fexofenadine (terfenadine), and levocetirizine (cetirizine)—and, hence, will also be referred to as second-generation antihistamines since there are no significant changes from the parent compound.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref>,<xref ref-type="bibr" rid="bibr8-2150129712472334">8</xref></sup> These options have been shown to have less sedation, no associated driving impairment, and reduced anticholinergic effects compared to first-generation products.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr7-2150129712472334">7</xref></sup> Interestingly, desloratadine (and its parent compound loratadine) and fexofenadine are the only antihistamines approved for use (with a medical waiver) from the Federal Aviation Administration.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref>,<xref ref-type="bibr" rid="bibr8-2150129712472334">8</xref></sup> Of the antihistamines, fexofenadine is considered to have the best therapeutic index and has the lowest incidence of sedation, varying from 1% to 3%.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref>,<xref ref-type="bibr" rid="bibr9-2150129712472334">9</xref></sup> Of the third-generation antihistamines, fexofenadine is the only one, however, that has CYP3A4 drug interaction considerations.<sup><xref ref-type="bibr" rid="bibr3-2150129712472334">3</xref></sup> In addition, fexofenadine is unique with its drug interaction with antacids; therefore, patients should be counseled to separate the administration of the 2 drug classes by as much time as possible.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref>,<xref ref-type="bibr" rid="bibr10-2150129712472334">10</xref></sup> Similar to the second-generation antihistamines, this grouping also has a longer duration of action allowing for once daily administration.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup> Desloratadine is the only one that has both renal and hepatic dosage adjustments.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref>,<xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref></sup></p>
<p>Many studies have evaluated the effect of the third-generation antihistamines on nasal decongestion.<sup><xref ref-type="bibr" rid="bibr11-2150129712472334">11</xref><xref ref-type="bibr" rid="bibr12-2150129712472334"/><xref ref-type="bibr" rid="bibr13-2150129712472334"/>-<xref ref-type="bibr" rid="bibr14-2150129712472334">14</xref></sup> Day and colleagues<sup><xref ref-type="bibr" rid="bibr14-2150129712472334">14</xref></sup> evaluated levocetirizine and desloratadine and found both to be well tolerated and effective; however, levocetirizine was found to be superior both in efficacy and reduction of nasal congestion. It is believed that levocetirizine has even more selectivity at the peripheral H<sub>1</sub> receptors than the other third-generation antihistamines.<sup><xref ref-type="bibr" rid="bibr14-2150129712472334">14</xref>,<xref ref-type="bibr" rid="bibr15-2150129712472334">15</xref></sup></p>
<p>Whether it is a first-, second-, or third-generation antihistamine being recommended or used, general efficacy is similar across all products when used for allergic rhinitis and/or urticaria.<sup><xref ref-type="bibr" rid="bibr4-2150129712472334">4</xref></sup> With the exception of fexofenadine and loratadine, all second- or third-generation antihistamines have a labeled indication for both seasonal and perennial allergic rhinitis.<sup><xref ref-type="bibr" rid="bibr2-2150129712472334">2</xref></sup> However, if one antihistamine fails to provide relief when used daily, patients may receive benefit from switching to another antihistamine.<sup><xref ref-type="bibr" rid="bibr16-2150129712472334">16</xref></sup> The choice of first-generation agent versus a second- or third-generation agent will likely depend more on their adverse effect profile. When choosing optimal therapy for patients, medication cost, adverse effect profile, and pharmacodynamics should be considered.</p>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2150129712472334">
<label>1.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Skidgel</surname><given-names>RA</given-names></name>
<name><surname>Kaplan</surname><given-names>AP</given-names></name>
<name><surname>Erdos</surname><given-names>EG</given-names></name>
</person-group>. <article-title>Chapter 32. Histamine, bradykinin, and their antagonists</article-title>. In: <person-group person-group-type="editor">
<name><surname>Chabner</surname><given-names>BA</given-names></name>
<name><surname>Brunton</surname><given-names>LL</given-names></name>
<name><surname>Knollman</surname><given-names>BC</given-names></name>
</person-group>, eds. <source>Goodman &amp; Gilman’s The Pharmacological Basis of Therapeutics</source>. <edition>12th ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill</publisher-name>; <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www.accesspharmacy.com/content.aspx?aID=16669775">http://www.accesspharmacy.com/content.aspx?aID=16669775</ext-link>. <access-date>Accessed November 8, 2012</access-date>.</citation>
</ref>
<ref id="bibr2-2150129712472334">
<label>2.</label>
<citation citation-type="book">
<collab>Lexi-Comp Online™</collab>. <article-title>Pediatric Lexi-Drugs Online™</article-title>. <publisher-loc>Hudson, OH</publisher-loc>: <publisher-name>Lexi-Comp, Inc</publisher-name>; <month>November</month> <volume>8</volume>, <year>2012</year>.</citation>
</ref>
<ref id="bibr3-2150129712472334">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wallace</surname><given-names>DV</given-names></name>
<name><surname>Dykewicz</surname><given-names>MS</given-names></name>
<name><surname>Bernstein</surname><given-names>DI</given-names></name><etal/>
</person-group>. <article-title>The diagnosis and management of rhinitis: an updated practice parameter</article-title>. <source>J Allergy Clin Immunol</source>. <year>2008</year>;<volume>122</volume>(<supplement>2 suppl</supplement>):<fpage>S1</fpage>-<lpage>S84</lpage>.</citation>
</ref>
<ref id="bibr4-2150129712472334">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bousquet</surname><given-names>J</given-names></name>
<name><surname>Khaltaev</surname><given-names>N</given-names></name>
<name><surname>Cruz</surname><given-names>AA</given-names></name><etal/>
</person-group>. <article-title>Allergic rhinitis and its impact on asthma (ARIA) 2008 update</article-title>. <source>Allergy</source>. <year>2008</year>;<volume>63</volume>(<supplement>suppl 86</supplement>):<fpage>8</fpage>-<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr5-2150129712472334">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simons</surname><given-names>FE</given-names></name>
</person-group>. <article-title>Advances in H1-antihistamines</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>:<fpage>2203</fpage>-<lpage>2217</lpage>.</citation>
</ref>
<ref id="bibr6-2150129712472334">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Hoecke</surname><given-names>H</given-names></name>
<name><surname>Vandenbulcke</surname><given-names>L</given-names></name>
<name><surname>Van Cauwenberge</surname><given-names>P</given-names></name>
</person-group>. <article-title>Histamine and leukotriene receptor antagonism in the treatment of allergic rhinitis: an update</article-title>. <source>Drugs</source>. <year>2007</year>;<volume>67</volume>:<fpage>2717</fpage>-<lpage>2726</lpage>.</citation>
</ref>
<ref id="bibr7-2150129712472334">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dykewicz</surname><given-names>MS</given-names></name>
<name><surname>Fineman</surname><given-names>S</given-names></name>
<name><surname>Skoner</surname><given-names>DP</given-names></name><etal/>
</person-group>. <article-title>Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology</article-title>. <source>Ann Allergy Asthma Immunol</source>. <year>1998</year>;<volume>81</volume>(<issue>5</issue> <supplement>pt 2</supplement>):<fpage>478</fpage>-<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr8-2150129712472334">
<label>8.</label>
<citation citation-type="book">
<collab>Federal Aviation Administration</collab>. <source>Federal Air Surgeon’s Medical Bulletin</source> (<volume>Vol. 48</volume>, <issue>No. 1</issue>). <publisher-loc>Oklahoma City, OK</publisher-loc>: <publisher-name>US Department of Transportation and Federal Aviation Administration</publisher-name>.</citation>
</ref>
<ref id="bibr9-2150129712472334">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holgate</surname><given-names>ST</given-names></name>
<name><surname>Canonica</surname><given-names>GW</given-names></name>
<name><surname>Simons</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations</article-title>. <source>Clin Exp Allergy</source>. <year>2003</year>;<volume>33</volume>:<fpage>1305</fpage>-<lpage>1324</lpage>.</citation>
</ref>
<ref id="bibr10-2150129712472334">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DuBuske</surname><given-names>LM</given-names></name>
</person-group>. <article-title>Pharmacokinetics/pharmacodynamics and psychomotor performance aspects of antihistamine therapies</article-title>. <source>Clin Appl Immunol Rev</source>. <year>2001</year>;<volume>1</volume>:<fpage>277</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr11-2150129712472334">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potter</surname><given-names>PC</given-names></name>
</person-group>. <article-title>Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites</article-title>. <source>Allergy</source>. <year>2003</year>;<volume>58</volume>:<fpage>893</fpage>-<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr12-2150129712472334">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horak</surname><given-names>F</given-names></name>
<name><surname>Stubner</surname><given-names>UP</given-names></name>
<name><surname>Zieglmayer</surname><given-names>R</given-names></name>
<name><surname>Harris</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit</article-title>. <source>J Allergy Clin Immunol</source>. <year>2002</year>;<volume>109</volume>:<fpage>956</fpage>-<lpage>961</lpage>.</citation>
</ref>
<ref id="bibr13-2150129712472334">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>DY</given-names></name>
<name><surname>Hanotte</surname><given-names>F</given-names></name>
<name><surname>De Vos</surname><given-names>C</given-names></name>
<name><surname>Clement</surname><given-names>P</given-names></name>
</person-group>. <article-title>Effect of cetirizine, levocetirizine and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers</article-title>. <source>Allergy</source>. <year>2001</year>;<volume>56</volume>:<fpage>339</fpage>-<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr14-2150129712472334">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Day</surname><given-names>JH</given-names></name>
<name><surname>Briscoe</surname><given-names>MP</given-names></name>
<name><surname>Rafeiro</surname><given-names>E</given-names></name>
<name><surname>Ratz</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU)</article-title>. <source>Int J Clin Pract</source>. <year>2004</year>;<volume>58</volume>:<fpage>109</fpage>-<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr15-2150129712472334">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Denham</surname><given-names>KJ</given-names></name>
<name><surname>Boutsiouki</surname><given-names>P</given-names></name>
<name><surname>Clough</surname><given-names>GF</given-names></name>
<name><surname>Church</surname><given-names>MK</given-names></name>
</person-group>. <article-title>Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin</article-title>. <source>Inflamm Res</source>. <year>2003</year>;<volume>52</volume>:<fpage>424</fpage>-<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr16-2150129712472334">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prenner</surname><given-names>BM</given-names></name>
</person-group>. <article-title>Comparative efficacy of antihistamines in allergic rhinitis and urticarial</article-title>. <source>Clin Appl Immunol Rev</source>. <year>2001</year>;<volume>1</volume>:<fpage>217</fpage>-<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr17-2150129712472334">
<label>17.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Briggs</surname><given-names>GG</given-names></name>
<name><surname>Freeman</surname><given-names>RK</given-names></name>
<name><surname>Yaffe</surname><given-names>S</given-names></name>
</person-group>, eds. <source>Drugs in Pregnancy and Lactation</source>. <edition>8th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lipincott Williams &amp; Wilkins</publisher-name>; <year>2008</year>: <fpage>205</fpage>, <fpage>258</fpage>, <fpage>305</fpage>, <fpage>325</fpage>, <fpage>382</fpage>, <fpage>454</fpage>, <fpage>496</fpage>, <fpage>501</fpage>, <fpage>553</fpage>, <fpage>718</fpage>, <fpage>899</fpage>, <fpage>1072</fpage>.</citation>
</ref>
<ref id="bibr18-2150129712472334">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hur</surname><given-names>SY</given-names></name>
</person-group>. <article-title>Allergic rhinitis</article-title>. <source>The Rx Consultant</source>. <year>2007</year>;<volume>16</volume>(<issue>3</issue>):<fpage>1</fpage>-<lpage>8</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>